Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)

Completed · Phase 3

Conditions studied: Osteoarthritis, Knee, Osteoarthritis, Hip, Chronic Low Back Pain

In brief

A study to show the safety of COV155 in patients with osteoarthritis of the knee or hip or moderate to severe chronic low back pain.

Key facts

Study ID

NCT01722864

Run by

Mallinckrodt

People needed

153

Starts

2012-11-01

Expected to finish

2013-08-01

Last updated by the study team

2016-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• General good health, other than osteoarthritis (OA) or chronic low back pain (CLBP), based upon results of medical and surgical history and medical exam
• ≥18 years of age
• Voluntarily provide written informed consent
• Female subjects eligible if
• Not pregnant or lactating; not planning to become pregnant within next 60 days
• Surgically sterile, or 2 years postmenopausal, or practicing acceptable birth control for more than 60 days prior to Screening and use of acceptable birth control during the study and 7 days following the last dose of COV155
• Male subjects biologically capable of having children must use reliable birth control during study and 7 days after the last dose of COV155. Surgical sterilization of the subject's monogamous partner qualifies as adequate birth control
• Clinical diagnosis of one of the following
• OA of knee or hip for at least 1 year with moderate to severe daily pain despite chronic use of stable doses of non-steroidal anti-inflammatory drugs (NSAIDs) or other non-steroidal, non-opioid therapies or with therapy including opioids
• Moderate to severe CLBP for at least several hours a day for a minimum of 90 days, not due to a known malignancy, and classified as non-neuropathic, neuropathic, or symptomatic for more than 6 months after LBP surgery
• OA of knee and scheduled to undergo unilateral primary tricompartmental arthroplasty.
• For CLBP/OA: Average in-clinic pain score of ≥3 on 11-point (0 to 10) numerical rating scale (NRS) as an average for the last 24 hours at Screening; - Pain intensity score of ≥4 on NRS as an average for the last 24 hours at Baseline
• For TKR: 11. Post-operative pain intensity scores ≥ 4 on a 0 to 10 NRS after discontinuation of post-surgical patient controlled analgesia or intravenous pain medications; body mass index ≤ 38.0; classified as either Physical Status (PS)-1 or PS-2.

You may not qualify if…

• Any clinically significant condition or unstable illness that precludes study participation or interferes with assessment of pain and other symptoms of CLBP or OA or would increase the risk of opioid or NSAID related adverse events
• Schizophrenia or an uncontrolled or poorly controlled major psychiatric condition or clinically significant anxiety or depression
• Active malignancy or history of malignancy within 2 years prior to Screening other than dermal or cervical squamous cell carcinoma in situ
• History of seizures (exception-pediatric febrile seizures)
• Clinically significant ECG abnormalities or uncontrolled hypo- or hypertension
• For CLBP/OA: Arthroscopic or open surgery on either the knee or hip selected as primary OA study joint within 6 months prior to Screening; - For CLBP subjects, a surgical procedure for back pain within 6 months prior to Screening, nerve or plexus block within 30 days prior to Screening or botulinum toxin injection in lower back region within 90 days prior to Screening. For OA subjects, joint injection within 30 days prior to Screening; - Surgical implants of either the knee or hip selected as the primary OA joint; history of spinal stenosis (only CLBP subjects)
• For TKR: Major prior open knee surgery on same side as arthroplasty; any other surgery/elective procedures within 4 weeks of Screening, or during study; going to rehabilitation after surgery
• Gastric reduction or gastric band surgery
• Taking opioids in equivalents to more than 20 mg hydrocodone or more than 40 mg morphine orally per day, or taking opioid medications 4 days a week or more
• Known allergy or hypersensitivity to opioids, acetaminophen or ibuprofen
• Certain lab abnormalities
• Unable to discontinue use of prohibited medications or history of substance or alcohol abuse within 2 years prior to Screening or positive urine drug test at Screening for alcohol, illicit drugs (including medical cannabis) or controlled substances other than prescribed medications
• Positive for human immunodeficiency virus, hepatitis B (surface antigen), and/or hepatitis C
• Any other chronic pain condition other than CLBP or OA that would interfere with the assessment of CLBP or OA
• Used a monoamine oxidase inhibitor, antipsychotic, or benzodiazepine within 14 days prior to Screening or started or changed doses of anticonvulsants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, or tricyclic antidepressants within 30 days prior to Screening
• Previously received COV155 in a study
• Received any investigational drugs or devices within 30 days prior to Screening
• Other criteria as specified in the protocol

Where it is running

• Anaheim Clinical Trials — Anaheim, California, United States
• Orange County Research Institute — Anaheim, California, United States
• United Clinical Research Center, Inc. — Anaheim, California, United States
• Torrance Clinical Research Inc. — Lomita, California, United States
• Probe Clinical Research Corporation - Santa Ana — Santa Ana, California, United States
• Lake Internal Medicine Associates — Eustis, Florida, United States
• Palm Springs Research Institute — Hialeah, Florida, United States
• Eastern Research — Hialeah, Florida, United States
• Health Awareness, Inc. — Jupiter, Florida, United States
• Clinical Neuroscience Solutions Inc. — Orlando, Florida, United States
• Compass Research, LLC — Orlando, Florida, United States
• Martin E. Hale, MD PA (Gold Coast Research LLC) — Plantation, Florida, United States
• Accord Clinical Research, LLC — Port Orange, Florida, United States
• International Clinical Research, LLC — Sanford, Florida, United States
• MediSphere Medical Research Center, LLC — Evansville, Indiana, United States
• Goldpoint Clinical Research — Indianapolis, Indiana, United States
• Beacon Clinical Research, LLC — Brockton, Massachusetts, United States
• Independent Clinical Researchers — Las Vegas, Nevada, United States
• Clinical Study Center of Asheville, LLC — Asheville, North Carolina, United States
• Wake Research Associates LLC — Raleigh, North Carolina, United States
• The Center for Clinical Research LLC — Winston-Salem, North Carolina, United States
• New Horizons Clinical Research — Cincinnati, Ohio, United States
• Hightop Physicians Inc./Medical Research Center — Cincinnati, Ohio, United States
• Community Research — Cincinnati, Ohio, United States
• Community Research - Anderson — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.